WELCOME TO The Biotechnology REPORT
Arwan Pharmaceutical Industries, Lebanon
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CELL AND GENE THERAPY
BeiGene | November 23, 2021
BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists.
TYK2 is a member of the JAK family and functions as a critical mediator in cytokine signaling pathways implicated in multiple immune-mediated disorders, such as psor...
Exothera | June 15, 2022
Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L.
Adeno-associated viruses (AAV) are non-enveloped, non-pathogenic viruses largely used as drug delivery vectors for biotherapeutics, like gene therapies and vaccines. Although the application of AAV is spreading rapidly, the industry is struggling to find cost-effecti...
Enzychem Lifesciences | March 03, 2022
Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18.
After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation&ndash...
Alnylam Pharmaceuticals | September 22, 2022
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced the appointment of two new members to the management team – Piyush Sharma as Chief Ethics & Compliance Officer and Evan Lippman in the newly created role of Chief Corporate Development and Strategy Officer. Both executives will report to Chief Executive Officer, Yvonne Greenstreet.
“Attracting and retaining top talent is one of my top priorities, and I’m thril...
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE